From: Proteomic profiling of breast cancer metabolism identifies SHMT2 and ASCT2 as prognostic factors
Characteristics | Univariate analysis | SHMT2 | ASCT2 | ||
---|---|---|---|---|---|
Multivariate analysis | Multivariate analysis | ||||
P value | Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | |
Protein expression high vs. low | 1.54 (1.16–2.04) | 0.003 | 1.31 (1.01–1.71) | 0.042 | |
Age at surgery (years) | <0.001 | 1.04 (1.02–-1.07) | <0.001 | 1.04 (1.02–1.06) | <0.001 |
Tumor size | <0.001 | Not included | Not included | ||
<2 cm | |||||
≥ 2–5 cm | |||||
>5 cm | |||||
Histology | 0.11 | Not included | Not included | ||
Ductal vs. non-ductal | |||||
T stage | <0.001 | ||||
T1 vs. ≥T2 | 1.77 (1.15–2.74) | 0.01 | 1.80 (1.16–2.80) | 0.009 | |
Grade | <0.001 | ||||
I | Reference | Reference | |||
II | 1.79 (0.65–4.98) | 0.262 | 1.85 (0.66–5.14) | 0.24 | |
III | 2.18 (0.75–6.35) | 0.154 | 2.64 (0.92–7.59) | 0.072 | |
Nodal status | <0.001 | ||||
N0 vs. ≥N1 | 1.62 (1.10–2.40) | 0.015 | 1.59 (1.07–2.35) | 0.021 | |
Menopausal status | 0.01 | ||||
Pre/peri vs. postmenopausal | 0.65 (0.31–1.38) | 0.263 | 0.73 (0.35–1.54) | 0.41 | |
Receptor status | |||||
ER- vs. ER+ | <0.001 | Not included | Not included | ||
PgR- vs. PgR+ | <0.001 | Not included | Not included | ||
HER2- vs. HER2+ | 0.489 | Not included | Not included | ||
HR- vs. HR+ | <0.001 | 0.79 (0.49–1.27) | 0.334 | 0.69 (0.43–1.10) | 0.115 |
Receptor-defined subtypes | <0.001 | Not included | Not included | ||
Luminal A-like | |||||
Luminal B-like (HER2 positive) | |||||
Luminal B-like (HER2 negative) | |||||
HER2 positive (non-luminal-like) | |||||
TNBC |